Pablo Alonso-Coello1, Victor M Montori2, M Gloria Díaz3, Philip J Devereaux4, Gemma Mas1, Ana I Diez5, Ivan Solà1, Mercè Roura6, Juan C Souto7, Sven Oliver8, Rafael Ruiz9, Blanca Coll-Vinent10, Ignasi Gich1, Holger J Schünemann4, Gordon Guyatt4. 1. Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau-CIBER of Epidemiology and Public Health (CIBERESP- IIB Sant Pau), Barcelona, Spain. 2. Knowledge and Encounter Research Unit, Mayo Clinic, Rochester, MN, USA. 3. Unidad Docente de Medicina Familiar y Comunitaria, Hospital Donostia, Donostia, Spain. 4. Department of Clinical Epidemiology & Biostatistics, CLARITY Research Group, McMaster University Medical Centre 2C9, Hamilton, ON, Canada. 5. Centro de Salud de Beraun, Errenteria, San Sebastián, Spain. 6. SAP Litoral de Barcelona, Barcelona, Spain. 7. Unitat d'Hemostàsia i Trombosi, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. 8. Unidad Formadora de Medicina Familiar y Comunitaria de A Coruña, Coruña, Spain. 9. Institut Català de la Salut, Barcelona, Spain. 10. Hospital Clínic, Barcelona, Spain.
Abstract
BACKGROUND: Exploration of values and preferences in the context of anticoagulation therapy for atrial fibrillation (AF) remains limited. To better characterize the distribution of patient and physician values and preferences relevant to decisions regarding anticoagulation in patients with AF, we conducted interviews with patients at risk of developing AF and physicians who manage patients with AF. METHODS: We interviewed 96 outpatients and 96 physicians in a multicenter study and elicited the maximal increased risk of bleeding (threshold risk) that respondents would tolerate with warfarin vs. aspirin to achieve a reduction in three strokes in 100 patients over a 2-year period. We used the probabilistic version of the threshold technique. RESULTS: The median threshold risk for both patients and physicians was 10 additional bleeds (10 P = 0.7). In both groups, we observed large variability in the threshold number of bleeds, with wider variability in patients than clinicians [patient range: 0-100, physician range: 0-50]. We observed one cluster of patients and physicians who would tolerate <10 bleeds and another cluster of patients, but not physicians, who would accept more than 35. CONCLUSIONS: Our findings suggest wide variability in patient and physician values and preferences regarding the trade-off between strokes and bleeds. Results suggest that in individual decision making, physician and patient values and preferences will often be discordant; this mandates tailoring treatment to the individual patient's preferences.
BACKGROUND: Exploration of values and preferences in the context of anticoagulation therapy for atrial fibrillation (AF) remains limited. To better characterize the distribution of patient and physician values and preferences relevant to decisions regarding anticoagulation in patients with AF, we conducted interviews with patients at risk of developing AF and physicians who manage patients with AF. METHODS: We interviewed 96 outpatients and 96 physicians in a multicenter study and elicited the maximal increased risk of bleeding (threshold risk) that respondents would tolerate with warfarin vs. aspirin to achieve a reduction in three strokes in 100 patients over a 2-year period. We used the probabilistic version of the threshold technique. RESULTS: The median threshold risk for both patients and physicians was 10 additional bleeds (10 P = 0.7). In both groups, we observed large variability in the threshold number of bleeds, with wider variability in patients than clinicians [patient range: 0-100, physician range: 0-50]. We observed one cluster of patients and physicians who would tolerate <10 bleeds and another cluster of patients, but not physicians, who would accept more than 35. CONCLUSIONS: Our findings suggest wide variability in patient and physician values and preferences regarding the trade-off between strokes and bleeds. Results suggest that in individual decision making, physician and patient values and preferences will often be discordant; this mandates tailoring treatment to the individual patient's preferences.
Authors: V Fuster; L E Rydén; R W Asinger; D S Cannom; H J Crijns; R L Frye; J L Halperin; G N Kay; W W Klein; S Lévy; R L McNamara; E N Prystowsky; L S Wann; D G Wyse Journal: Eur Heart J Date: 2001-10 Impact factor: 29.983
Authors: Carl van Walraven; Robert G Hart; Daniel E Singer; Andreas Laupacis; Stuart Connolly; Palle Petersen; Peter J Koudstaal; Yuchiao Chang; Beppie Hellemons Journal: JAMA Date: 2002-11-20 Impact factor: 56.272
Authors: Richard G Thomson; Martin P Eccles; I Nick Steen; Jane Greenaway; Lynne Stobbart; Madeleine J Murtagh; Carl R May Journal: Qual Saf Health Care Date: 2007-06
Authors: Theodore Wein; M Patrice Lindsay; David J Gladstone; Alexandre Poppe; Alan Bell; Leanne K Casaubon; Norine Foley; Shelagh B Coutts; Jafna Cox; James Douketis; Thalia Field; Laura Gioia; Jeffrey Habert; Eddy Lang; Shamir R Mehta; Christine Papoushek; William Semchuk; Mikul Sharma; Jacob A Udell; Stephanie Lawrence; Anita Mountain; Gord Gubitz; Dar Dowlatshahi; Anne Simard; Andrea de Jong; Eric E Smith Journal: CMAJ Date: 2020-10-05 Impact factor: 8.262
Authors: Theodore Wein; M Patrice Lindsay; David J Gladstone; Alexandre Poppe; Alan Bell; Leanne K Casaubon; Norine Foley; Shelagh B Coutts; Jafna Cox; James Douketis; Thalia Field; Laura Gioia; Jeffrey Habert; Eddy Lang; Shamir R Mehta; Christine Papoushek; William Semchuk; Mikul Sharma; Jacob A Udell; Stephanie Lawrence; Anita Mountain; Gord Gubitz; Dar Dowlatshahi; Anne Simard; Andrea de Jong; Eric E Smith Journal: CMAJ Date: 2020-03-23 Impact factor: 8.262
Authors: Claudia L Zeballos-Palacios; Ian G Hargraves; Peter A Noseworthy; Megan E Branda; Marleen Kunneman; Bruce Burnett; Michael R Gionfriddo; Christopher J McLeod; Haeshik Gorr; Juan Pablo Brito; Victor M Montori Journal: Mayo Clin Proc Date: 2019-01-11 Impact factor: 7.616
Authors: Jeffrey M Ashburner; Steven J Atlas; Shaan Khurshid; Lu-Chen Weng; Olivia L Hulme; Yuchiao Chang; Daniel E Singer; Patrick T Ellinor; Steven A Lubitz Journal: J Gen Intern Med Date: 2018-08-03 Impact factor: 6.473
Authors: Misericòrdia Carles; Max Brosa; Juan Carlos Souto; Josep Maria Garcia-Alamino; Gordon Guyatt; Pablo Alonso-Coello Journal: BMC Health Serv Res Date: 2015-07-28 Impact factor: 2.655
Authors: Lyubov Lytvyn; Gordon H Guyatt; Veena Manja; Reed A Siemieniuk; Yuan Zhang; Thomas Agoritsas; Per O Vandvik Journal: BMJ Open Date: 2016-09-29 Impact factor: 2.692